脂質奈米顆粒在mRNA疫苗技術應用發展綜述

、線上人數：14

、訪客IP：3.142.198.129

姓名	葉咨甫(YEH TZU FU) 查詢紙本館藏	畢業系所	跨領域轉譯醫學研究所
論文名稱	脂質奈米顆粒在mRNA疫苗技術應用發展綜述 (A review of technological developments in lipid nanoparticle application for mRNA vaccination)
檔案	[Endnote RIS 格式] [Bibtex 格式] [相關文章] [文章引用] [完整記錄] [館藏目錄] 至系統瀏覽論文 (2026-1-24以後開放)
摘要(中)	本研究深入探討了脂質納米粒子（LNP）技術在mRNA領域的專利格局，並分析了其在生物醫學領域的技術創新。研究旨在揭示技術創新是否遵循技術線性模型，同時深入研究核心技術團隊、關鍵專利以及相關疫苗專利的發展。過往研究對於LNP技術和mRNA疫苗的專利格局及專利糾紛關注不足，本研究填補了這一空白。我們透過文獻引用分析、專利分析、專利訴訟案例研究等多元方法，詳細梳理了LNP技術的專利現狀，並探討了專利叢林對技術創新的影響及專利豁免政策的實際效果。本研究發現，LNP技術在mRNA疫苗開發中發揮了關鍵作用，其創新過程符合技術線性模型。研究還指出，專利格局及市場競爭格局中，賓州大學和麻省理工學院等學術機構在基礎研究上作出了顯著貢獻，而Moderna、BioNTech等公司在專利申請和市場競爭中佔有重要地位。此外，專利叢林現象和專利訴訟案例顯示，專利權的行使可能對技術創新和公共衛生利益產生重大影響。綜上所述，本研究不僅深入分析了LNP技術在mRNA領域的專利狀況，還探討了專利政策對技術創新和公共衛生的複雜影響，為相關利益者提供了寶貴的見解和策略建議，有助於促進技術創新並維護公共利益。
摘要(英)	This study delves into the patent landscape of Lipid Nanoparticle (LNP) technology in the mRNA field and analyzes its technological innovation in the biomedical domain. It aims to reveal whether technological innovation follows the linear model of technology and examines in-depth the core technical teams, key patents, and the development of related vaccine patents.Previous research has inadequately focused on the patent landscape and disputes concerning LNP technology and mRNA vaccines. This study fills this gap. Employing diverse methodologies such as literature citation analysis, patent analysis, and case studies of patent litigation, we comprehensively outline the current patent status of LNP technology and discuss the impact of patent thickets on technological innovation, along with the practical effects of patent exemption policies. Our findings indicate that LNP technology plays a pivotal role in the development of mRNA vaccines, aligning with the linear model of technology innovation. The study also identifies significant contributions of academic institutions such as the University of Pennsylvania and MIT in basic research, while companies like Moderna and BioNTech hold significant positions in patent applications and market competition. Furthermore, phenomena like patent thickets and cases of patent litigation suggest that the exercise of patent rights can significantly impact technological innovation and public health interests. In summary, this research not only analyzes in depth the patent status of LNP technology in the mRNA field but also explores the complex impact of patent policies on technological innovation and public health. It provides valuable insights and strategic recommendations for stakeholders, aiding in the promotion of technological innovation and the safeguarding of public interests.
關鍵字(中)	★ 脂質奈米顆粒 ★ mRNA 疫苗 ★ COVID-19 ★ 期刊分析 ★ 專利分析 ★ 生物醫藥專利	關鍵字(英)	★ Lipid Nanoparticle (LNP) ★ mRNA vaccine ★ COVID-19 ★ journal analysis ★ patent analysis ★ biomedical patents
論文目次	目錄中文摘要 ·································································································vii 英文摘要 ································································································viii 致謝 ········································································································ix 目錄 ·········································································································x 圖目錄 ···································································································xiii 表目錄 ···································································································xiv 一、緒論： ················································································- 1 - 1-1 研究動機 ·············································································- 1 - 1-2 本研究之貢獻 ·······································································- 2 - 1-3 章節介紹 ·············································································- 3 - 二、文獻回顧 ·············································································- 5 - 2-1 全球新冠疫情的挑戰與 mRNA 疫苗的崛起 ··································- 5 - 2-2 mRNA 疫苗在 COVID-19 中的關鍵作用 ······································- 7 - 2-3 mRNA 疫苗與 LNP 技術的發展歷程 ··········································- 10 - 2-3-1 mRNA 疫苗介紹 ···································································- 10 - 2-3-2 LNP 遞送技術發展與在 mRNA 疫苗中的重要性 ···························- 12 - 2-4 專利制度與生物醫學創新 ·······················································- 14 - 2-4-2 生物醫藥專利的發展背景 ·······················································- 15 - 2-4-3 創新線性模型 ······································································- 16 - 2-5 專利叢林與創新障礙 ·····························································- 18 - 2-5-2 反公地悲劇理論 ···································································- 19 - 2-5-3 專利叢林理論 ······································································- 19 - 2-5-4 關於生醫專利阻礙創新的實證研究 ···········································- 20 - 2-6 疫苗專利與公共衛生的衝突 ····················································- 21 - 2-7 小結 ··················································································- 23 - 三、創新線性理論研究及分析 ·······················································- 24 - 3-1 研究問題與研究方法 ·····························································- 24 - 3-2 研究方法 ············································································- 25 - 3-3 mRNA 疫苗與 LNP 技術發展概況 ·············································- 25 - 3-4 mRNA 與 LNP 技術的期刊與專利引用分析 ·································- 29 - 3-4-1 31 篇文章與專利引用關係·······················································- 29 - 3-4-2 21 件 mRNA 疫苗與 LNP 專利與文章引用關係·····························- 35 - 3-4-3 期刊作者與專利發明人的分析 ·················································- 40 - 3-5 小結 ··················································································- 45 - 四、 mRNA 與 LNP 技術領域的核心研發團隊 ····································- 46 - 4-1 關於 mRNA 和 LNP 專利研究文獻回顧 ······································- 46 - 4-2 研究方法 ············································································- 48 - 4-2-1 期刊資料庫 ·········································································- 48 - 4-2-2 專利資料庫 ·········································································- 49 - 4-2-3 選擇兩個資料庫之理由 ··························································- 49 - 4-2-4 檢索策略 ············································································- 50 - 4-3 核心研究團隊分析 ································································- 52 - 4-3-1 趨勢分析 ············································································- 52 - 4-3-2 期刊分析 ············································································- 56 - 4-3-3 專利分析 ············································································- 60 - 4-3-4 期刊與專利的相關性分析 ·······················································- 64 - 4-3-5 高引用的期刊分析 ································································- 69 - 4-4 小結 ··················································································- 71 - 五、 mRNA 與 LNP 技術的專利訴訟分析 ··········································- 73 - 5-1 前言 ··················································································- 73 - 5-2 mRNA 與 LNP 技術的專利訴訟分析 ··········································- 74 - 5-3 研究議題 ············································································- 83 - 5-3-1 八家領先企業的專利格局 ·······················································- 83 - 5-4 核心專利評估 ······································································- 92 - 5-4-1 參與訴訟專利評估 ································································- 93 - 5-4-2 專利引用和同族專利的評估 ····················································- 95 - 5-4-3 研究報告中的關鍵專利 ··························································- 98 - 5-4-4 LNP 專利格局分析 ································································- 99 - 5-5 小結 ················································································- 103 - 六、疫苗專利對技術創新的案例分析 ············································- 104 - 6-1 疫苗專利阻礙技術創新的研究 ···············································- 104 - 6-2 專利豁免案例研究 ······························································- 106 - 6-2-1 支持與反對專利豁免的立場 ··················································- 106 - 6-2-2 COVID-19 期間的自願授權 ···················································- 109 - 6-2-3 專利豁免政策對於疫苗生產商的影響 ······································- 113 - 6-3 小結 ················································································- 115 - 七、綜合討論 ··········································································- 117 - 7-1 創新線性模型是否適用於 LNP 技術在 mRNA 領域？ ··················- 117 - 7-2 當前 LNP 技術在 mRNA 領域的專利與市場競爭格局？ ···············- 118 - 7-3 LNP 技術在 mRNA 領域是否存在阻礙技術創新或限制疫苗流通？ ·- 119 - 7-4 小結 ················································································- 121 - 八、結論： ·············································································- 123 - 參考文獻 ····························································································- 125 - 附件 1 八家核心企業核心專利································································- 146 -
參考文獻	[1]東臺傳播：〈mRNA疫苗的發明〉, (Feb. 23, 2023). [Online Video]. 2024年1月24日，取自https://www.youtube.com/watch?v=LfdARvbT6MI [2]N. Chaudhary, D. Weissman, and K. A. Whitehead, “mRNA vaccines for infectious diseases: principles, delivery and clinical translation,” Nat Rev Drug Discov, vol. 20, no. 11, Art. no. 11, Nov. 2021, doi: 10.1038/s41573-021-00283-5. [3]R. C. Levin, A. K. Klevorick, R. Nelson, and S. Winter, “Appropriating the Returns from Industrial R&D,” Cowles Foundation for Research in Economics, Yale University, Cowles Foundation Discussion Paper 862, Feb. 1988. Accessed: Jan. 23, 2024. [Online]. Available: https://econpapers.repec.org/paper/cwlcwldpp/862.htm [4]The Nobel Prize, “The Nobel Prize in Physiology or Medicine 2023,” NobelPrize.org. Accessed: Dec. 10, 2023. [Online]. Available: https://www.nobelprize.org/prizes/medicine/2023/press-release/ [5]M. Li et al., “The global mRNA vaccine patent landscae,” Hum Vaccin Immunother, vol. 18, no. 6, p. 2095837, Nov. 2022, doi: 10.1080/21645515.2022.2095837. [6]WHO, “WHO Coronavirus (COVID-19) Dashboard.,” datadot. Accessed: Jan. 23, 2024. [Online]. Available: https://data.who.int [7]N. LePan, “Visualizing the History of Pandemics,” Visual Capitalist. Accessed: Jan. 23, 2024. [Online]. Available: https://www.visualcapitalist.com/history-of-pandemics-deadliest/ [8]B. L. Jr, “Covid is officially America’s deadliest pandemic as U.S. fatalities surpass 1918 flu estimates,” CNBC. Accessed: Jan. 23, 2024. [Online]. Available: https://www.cnbc.com/2021/09/20/covid-is-americas-deadliest-pandemic-as-us-fatalities-near-1918-flu-estimates.html [9]D. Adam, “The pandemic’s true death toll: millions more than official counts,” Nature, vol. 601, no. 7893, pp. 312–315, Jan. 2022, doi: 10.1038/d41586-022-00104-8. [10]D. Adam, “COVID’s true death toll: much higher than official records,” Nature, vol. 603, no. 7902, pp. 562–562, Mar. 2022, doi: 10.1038/d41586-022-00708-0. [11]Y. Dong and H. Wu, “The Collaborative Innovation between Patents and Standards: A New Path to Solve the Legal Dilemma of COVID-19 Vaccine Patenting.” Rochester, NY, Mar. 01, 2023. doi: 10.2139/ssrn.4373630. [12]R&D Blue Print (RDB), “COVID-19 vaccine tracker and landscape,” World Health Organization. Accessed: Jan. 23, 2024. [Online]. Available: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines [13]Gavi Staff, “There are four types of COVID-19 vaccines: here’s how they work \| Gavi, the Vaccine Alliance,” Gavi. Accessed: Jan. 23, 2024. [Online]. Available: https://www.gavi.org/vaccineswork/there-are-four-types-covid-19-vaccines-heres-how-they-work [14]WHO, “Coronavirus disease (COVID-19): Vaccines and vaccine safety,” WHO. Accessed: Jan. 23, 2024. [Online]. Available: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines [15]WHO, “COVID-19 vaccines technical documents,” WHO. Accessed: Jan. 23, 2024. [Online]. Available: https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/covid-19-materials [16]“Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing,” WHO. Accessed: Jan. 23, 2024. [Online]. Available: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1 [17] JON COHEN, “‘Incredible milestone for science.’ Pfizer and BioNTech update their promising COVID-19 vaccine result,” Science. Accessed: Jan. 23, 2024. [Online]. Available: https://www.science.org/content/article/covid-19-vaccine-trial-complete-pfizer-and-biontech-update-their-promising-result [18] DAN SHORES, “Breaking Down Moderna’s COVID-19 Patent Pledge: Why Did They Do It?,” IPWatchdog.com \| Patents & Intellectual Property Law. Accessed: Jan. 23, 2024. [Online]. Available: https://ipwatchdog.com/2020/11/11/breaking-modernas-covid-19-patent-pledge/id=127224/ [19] N. Pardi, M. J. Hogan, F. W. Porter, and D. Weissman, “mRNA vaccines — a new era in vaccinology,” Nat Rev Drug Discov, vol. 17, no. 4, Art. no. 4, Apr. 2018, doi: 10.1038/nrd.2017.243. [20] Our World in Data, “COVID-19 vaccine doses administered by manufacturer,” Our World in Data. Accessed: Jan. 23, 2024. [Online]. Available: https://ourworldindata.org/grapher/covid-vaccine-doses-by-manufacturer [21]M. Gaviria and B. Kilic, “A network analysis of COVID-19 mRNA vaccine patents,” Nat Biotechnol, vol. 39, no. 5, Art. no. 5, May 2021, doi: 10.1038/s41587-021-00912-9. [22]BioNTech, “BioNTech Pro – das Portal für Fachkreise,” BioNTech. Accessed: Jan. 23, 2024. [Online]. Available: https://pro.biontech.com/de/de/public.html [23]Emily Chung, and Amina Zafa, “Moderna, Pfizer-BioNTech vaccines have been approved in Canada. Here’s what you need to know about them \| CBC News,” CBC News. Accessed: Jan. 23, 2024. [Online]. Available: https://www.cbc.ca/news/health/covid-19-vaccine-pfizer-faq-1.5795486 [24] W. I. P. Organization (WIPO), “COVID-19-related vaccines and therapeutics,” World Intellectual Property Organization (WIPO). Accessed: Mar. 14, 2023. [Online]. Available: https://www.wipo.int/publications/en/details.jsp?id=4589 [25]Cell, “Learning lessons from lipids to make COVID-19 vaccines,” Cell, vol. 185, no. 8, pp. 1279–1282, Apr. 2022, doi: 10.1016/j.cell.2022.03.026. [26]Penn Medicine, “Katalin Kariko, PhD profile \| PennMedicine.org,” Penn Medicine. Accessed: Jan. 23, 2024. [Online]. Available: https://www.pennmedicine.org/providers/profile/katalin-kariko [27]很好設計, 〈唐獎得主彼得·庫利斯〉, tang-prize. 2024年1月24日，取自http://www.tang-prize.org/owner_detail.php?id=2036&cat=11 [28] M. Verma, I. Ozer, W. Xie, R. Gallagher, A. Teixeira, and M. Choy, “The landscape for lipid-nanoparticle-based genomic medicines,” Nat Rev Drug Discov, vol. 22, no. 5, pp. 349–350, May 2023, doi: 10.1038/d41573-023-00002-2. [29]EPO, “EPO patent insight report on mRNA technologies \| Epo.org,” EPO. Accessed: Jan. 23, 2024. [Online]. Available: https://www.epo.org/en/learning/events/ks27-2023 [30]E. W. Kitch, “The Nature and Function of the Patent System,” The Journal of Law and Economics, vol. 20, no. 2, pp. 265–290, Oct. 1977, doi: 10.1086/466903. [31]E. Mansfield, “Patents and Innovation: An Empirical Study,” Management Science, vol. 32, no. 2, pp. 173–181, Feb. 1986, doi: 10.1287/mnsc.32.2.173. [32]H. Gupta, S. Kumar, S. K. Roy, and R. S. Gaud, “Patent protection strategies,” J Pharm Bioallied Sci, vol. 2, no. 1, pp. 2–7, Jan. 2010, doi: 10.4103/0975-7406.62694. [33]T. A. Hemphill, “Preemptive patenting, human genomics, and the US biotechnology sector: balancing intellectual property rights with societal welfare,” Technology in Society, vol. 25, no. 3, pp. 337–349, Aug. 2003, doi: 10.1016/S0160-791X(03)00050-2. [34]N. Gallini, “Do patents work? Thickets, trolls and antibiotic resistance,” Canadian Journal of Economics/Revue canadienne d’économique, vol. 50, no. 4, pp. 893–926, 2017, doi: 10.1111/caje.12312. [35]Vannevar Bush, “Science, The Endless Frontier,” NSF. Accessed: Jan. 23, 2024. [Online]. Available: https://www.nsf.gov/about/history/nsf50/vbush1945.jsp [36]F. Narin and E. Noma, “Is technology becoming science?,” Scientometrics, vol. 7, no. 3, pp. 369–381, Mar. 1985, doi: 10.1007/BF02017155. [37]W. Glänzel and P. Zhou, “Publication activity, citation impact and bi-directional links between publications and patents in biotechnology,” Scientometrics, vol. 86, no. 2, pp. 505–525, Jul. 2010, doi: 10.1007/s11192-010-0269-6. [38]Z.-Y. Zhao and X.-P. Lei, “Empirical analysis of the relationship between technology innovation and basic research,” Current Science, vol. 104, no. 6, pp. 714–720, 2013. [39] Diamond v. Chakrabarty, 447 U.S. 303 (1980). 1980. Accessed: Jan. 23, 2024. [Online]. Available: https://supreme.justia.com/cases/federal/us/447/303/ [40]“Bayh-Dole Act,” drexel.edu. Accessed: Jan. 23, 2024. [Online]. Available: https://drexel.edu/research/innovation/technology-commercialization/bayh-dole-act/ [41]M. Kenney and D. Patton, “Reconsidering the Bayh-Dole Act and the Current University Invention Ownership Model,” Research Policy, vol. 38, no. 9, pp. 1407–1422, Nov. 2009, doi: 10.1016/j.respol.2009.07.007. [42]N. van Zeebroeck, B. van Pottelsberghe de la Potterie, and D. Guellec, “Patents and academic research: a state of the art,” Journal of Intellectual Capital, vol. 9, no. 2, pp. 246–263, Jan. 2008, doi: 10.1108/14691930810870328. [43]T. K. Tullis, “Current intellectual property issues in nanotechnology,” Nanotechnology Reviews, vol. 1, no. 2, pp. 189–205, Mar. 2012, doi: 10.1515/ntrev-2012-0501. [44] C. Sternitzke, “Knowledge sources, patent protection, and commercialization of pharmaceutical innovations,” Research Policy, vol. 39, no. 6, pp. 810–821, Jul. 2010, doi: 10.1016/j.respol.2010.03.001. [45]M. Kremer and C. M. Snyder, “Why Are Drugs More Profitable Than Vaccines?,” NBER Working Papers, Art. no. 9833, Jul. 2003, Accessed: Jan. 23, 2024. [Online]. Available: https://ideas.repec.org//p/nbr/nberwo/9833.html [46]古格里‧祖克曼,《疫苗商戰：新冠危機下AZ、BNT、輝瑞、莫德納、嬌生、Novavax的生死競賽》. 天下文化, 2022. Accessed: Jan. 23, 2024. [Online]. Available: https://www.books.com.tw/products/0010915408 [47]J. Lexchin, “One step forward, one step sideways? Expanding research capacity for neglected diseases,” BMC International Health and Human Rights, vol. 10, no. 1, p. 20, Jul. 2010, doi: 10.1186/1472-698X-10-20. [48]M. A. Heller and R. S. Eisenberg, “Can Patents Deter Innovation? The Anticommons in Biomedical Research,” Science, vol. 280, no. 5364, pp. 698–701, May 1998, doi: 10.1126/science.280.5364.698. [49]A. Colaianni and R. Cook-Deegan, “Columbia University’s Axel Patents: Technology Transfer and Implications for the Bayh-Dole Act,” Milbank Q, vol. 87, no. 3, pp. 683–715, Sep. 2009, doi: 10.1111/j.1468-0009.2009.00575.x. [50]M. Dodgson, D. M. Gann, and N. Phillips, The Oxford Handbook of Innovation Management. OUP Oxford, 2013. [51]A. P. Molella and N. Reingold, “Theorists and Ingenious Mechanics: Joseph Henry Defines Science,” Science Studies, vol. 3, no. 4, pp. 323–351, Oct. 1973, doi: 10.1177/030631277300300401. [52]J. D. Linton and W. Xu, “Understanding and Managing the Biotechnology Valley of Death,” Trends in Biotechnology, vol. 39, no. 2, pp. 107–110, Feb. 2021, doi: 10.1016/j.tibtech.2020.06.013. [53]A. Manjunath et al., “Comprehensive analysis of 2.4 million patent-to-research citations maps the biomedical innovation and translation landscape,” Nat Biotechnol, vol. 39, no. 6, Art. no. 6, Jun. 2021, doi: 10.1038/s41587-021-00940-5. [54] F. Narin, K. S. Hamilton, and D. Olivastro, “The increasing linkage between U.S. technology and public science,” Research Policy, vol. 26, no. 3, pp. 317–330, Oct. 1997, doi: 10.1016/S0048-7333(97)00013-9. [55]N. Rosenberg and L. E. Birdzell, “Science, Technology and the Western Miracle,” Scientific American, vol. 263, no. 5, pp. 42–55, 1990. [56]National Science Foundation, “National Science Foundation FY 1952 Annual Report,” United States Government Printing Office., Washington, DC:, 1952. Accessed: Jan. 23, 2024. [Online]. Available: https://www.nsf.gov/pubs/1952/annualreports/start.htm [57]M. Meyer, “Does science push technology? Patents citing scientific literature,” Research Policy, vol. 29, no. 3, pp. 409–434, Mar. 2000, doi: 10.1016/S0048-7333(99)00040-2. [58]Q. Ke, “An analysis of the evolution of science-technology linkage in biomedicine,” Journal of Informetrics, vol. 14, no. 4, p. 101074, Nov. 2020, doi: 10.1016/j.joi.2020.101074. [59]B. Z. Khan, “Ivory Tower and Industrial Innovation: University-Industry Technology Transfer Before and After the Bayh-Dole Act. By David C. Mowery, Richard R. Nelson, Bhaven N. Sampat and Arvids A. Ziedonis. Stanford, CA: Stanford Business Books, 2004. Pp. xiv, 241. $39.95.,” The Journal of Economic History, vol. 64, no. 4, pp. 1147–1148, Dec. 2004, doi: 10.1017/S0022050704293123. [60]G. S. McMillan, F. Narin, and D. L. Deeds, “An analysis of the critical role of public science in innovation: the case of biotechnology,” Research Policy, vol. 29, no. 1, pp. 1–8, Jan. 2000, doi: 10.1016/S0048-7333(99)00030-X. [61]“The Meaning of Translational Research and Why It Matters \| Research, Methods, Statistics \| JAMA \| JAMA Network.” Accessed: Jan. 23, 2024. [Online]. Available: https://jamanetwork.com/journals/jama/article-abstract/1149350 [62]A. Manjunath et al., “Who counts as an inventor? Seniority and gender in 430,000 biomedical inventor–researcher teams,” Nat Biotechnol, vol. 41, no. 5, Art. no. 5, May 2023, doi: 10.1038/s41587-023-01771-2. [63]C. Shapiro, “Navigating the Patent Thicket: Cross Licenses, Patent Pools, and Standard Setting,” Innovation Policy and the Economy, vol. 1, pp. 119–150, Jan. 2000, doi: 10.1086/ipe.1.25056143. [64]M. D. Buschmann, M. J. Carrasco, S. Alishetty, M. Paige, M. G. Alameh, and D. Weissman, “Nanomaterial Delivery Systems for mRNA Vaccines,” Vaccines, vol. 9, no. 1, Art. no. 1, Jan. 2021, doi: 10.3390/vaccines9010065. [65]G. Kroub, “3 Things The 2017 Patent Litigation Statistics Show Us - Above the Law.” Accessed: Jan. 23, 2024. [Online]. Available: https://abovethelaw.com/2018/02/3-things-the-2017-patent-litigation-statistics-show-us/ [66]F. Murray and S. Stern, “Do formal intellectual property rights hinder the free flow of scientific knowledge?: An empirical test of the anti-commons hypothesis,” Journal of Economic Behavior & Organization, vol. 63, no. 4, pp. 648–687, Aug. 2007, doi: 10.1016/j.jebo.2006.05.017. [67]B. H. Hall, C. Helmers, and G. von Graevenitz, “Technology Entry in the Presence of Patent Thickets,” Aug. 2015, doi: 10.3386/w21455. [68]J. P. Walsh, C. Cho, and W. M. Cohen, “Science and law. View from the bench: patents and material transfers,” Science, vol. 309, no. 5743, pp. 2002–2003, Sep. 2005, doi: 10.1126/science.1115813. [69]J. P. Walsh, W. M. Cohen, and C. Cho, “Where excludability matters: Material versus intellectual property in academic biomedical research,” Research Policy, vol. 36, no. 8, pp. 1184–1203, Oct. 2007, doi: 10.1016/j.respol.2007.04.006. [70]L. L. Ouellette, “Access to Bio-Knowledge: From Gene Patents to Biomedical Materials,” Stan. Tech. L. Rev., vol. 2010, p. N1, 2010. [71] A. Galasso and M. Schankerman, “Patents and Cumulative Innovation: Causal Evidence from the Courts *,” The Quarterly Journal of Economics, vol. 130, no. 1, pp. 317–369, Feb. 2015, doi: 10.1093/qje/qju029. [72]B. Sampat and H. L. Williams, “How Do Patents Affect Follow-On Innovation? Evidence from the Human Genome,” American Economic Review, vol. 109, no. 1, pp. 203–236, Jan. 2019, doi: 10.1257/aer.20151398. [73]J. Freilich and S. Shahshahani, “Measuring follow-on innovation,” Research Policy, vol. 52, no. 9, p. 104854, Nov. 2023, doi: 10.1016/j.respol.2023.104854. [74]Assoc. for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013). 2013. Accessed: Jan. 23, 2024. [Online]. Available: https://supreme.justia.com/cases/federal/us/569/576/ [75]G. Brown, “Vaccines for All or Vaccine Apartheid? \| by Gordon Brown,” Project Syndicate. Accessed: Jan. 23, 2024. [Online]. Available: https://www.project-syndicate.org/commentary/g7-must-finance-global-covid19-vaccination-drive-by-gordon-brown-2021-06 [76]Philip Schellekens, “Mapping our unvaccinated world.” Accessed: Jan. 23, 2024. [Online]. Available: https://pandem-ic.com/mapping-our-unvaccinated-world/ [77]“Rich Countries Must Stop Blocking the Covid Vaccine Patent Waiver \| Human Rights Watch.” Accessed: Jan. 23, 2024. [Online]. Available: https://www.hrw.org/news/2021/12/02/rich-countries-must-stop-blocking-covid-vaccine-patent-waiver [78]European Commission, “EU Vaccines Strategy - European Commission.” Accessed: Jan. 23, 2024. [Online]. Available: https://commission.europa.eu/strategy-and-policy/coronavirus-response/public-health/eu-vaccines-strategy_en [79]M. Liu, W. B. Feldman, J. Avorn, and A. S. Kesselheim, “March-In Rights And Compulsory Licensing—Safety Nets For Access To A COVID-19 Vaccine,” Health Affairs Forefront, Accessed: Jan. 23, 2024. [Online]. Available: https://www.healthaffairs.org/do/10.1377/forefront.20200501.798711/full/ [80]M. Florio, “Patents for Covid-19 vaccines are based on public research: a case study on the privatization of knowledge,” CIRIEC Working Papers, Art. no. 2103, Mar. 2021, Accessed: Jan. 23, 2024. [Online]. Available: https://ideas.repec.org//p/crc/wpaper/2103.html [81]M. Florio, “To what extent patents for Covid-19 mRNA vaccines are based on public research and taxpayers’ funding? A case study on the privatization of knowledge,” Industrial and Corporate Change, vol. 31, no. 5, pp. 1137–1151, Oct. 2022, doi: 10.1093/icc/dtac015. [82]Cormac O’Sullivan, Paul Rutten, and Caspar Schatz, “How COVID-19 vaccine production can ramp up \| McKinsey,” mckinsey,. Accessed: Jan. 23, 2024. [Online]. Available: https://www.mckinsey.com/industries/life-sciences/our-insights/why-tech-transfer-may-be-critical-to-beating-covid-19 [83]N. Garrido Cuenca, “Predicaments during a period of health emergency: Waiving patent protections or innovative public procurement? The example of advance purchase agreements (APA) for COVID-19 vaccines,” Int J Risk Saf Med, vol. 33, no. 2, pp. 145–156, 2022, doi: 10.3233/JRS-227008. [84]European Commission, “EU Vaccines Strategy.” Accessed: Mar. 27, 2023. [Online]. Available: https://commission.europa.eu/strategy-and-policy/coronavirus-response/public-health/eu-vaccines-strategy_en [85]LENs.ORG, “The Lens MetaRecord and LensID: An open identifier system for aggregated metadata and versioning of knowledge artefacts,” About The Lens. Accessed: Jan. 23, 2024. [Online]. Available: https://about.lens.org/the-lens-metarecord/ [86]Lens, “Which Institutions are Behind the Lens,” About The Lens. Accessed: Jan. 23, 2024. [Online]. Available: https://about.lens.org/which/ [87]WIPO, Chapter 9 The Lens \| The WIPO Manual on Open Source atent Analytics (2nd edition), vol. Chapter 9. 2022. Accessed: Jan. 23, 2024. [Online]. Available: https://wipo-analytics.github.io/manual/the-lens-1.html [88]S. Brenner, “An Unstable Intermediate Carrying Information from Genes to Ribosomes for Protein Synthesis,” Nature, vol. 190, pp. 576–581, May 1961, doi: 10.1038/190576a0. [89]M. Cobb, “Who discovered messenger RNA?,” Current Biology, vol. 25, no. 13, pp. R526–R532, Jun. 2015, doi: 10.1016/j.cub.2015.05.032. [90]G. Gregoriadis and B. E. Ryman, “Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases.,” Biochem J, vol. 124, no. 5, p. 58P, Oct. 1971. [91]A. C. Allison and G. Gregoriadis, “Liposomes as Immunological Adjuvants,” in Lymphocytes, Macrophages, and Cancer, G. Mathé, I. Florentin, and M.-C. Simmler, Eds., in Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer. , Berlin, Heidelberg: Springer, 1976, pp. 58–64. doi: 10.1007/978-3-642-81049-7_8. [92]“Direct Gene Transfer into Mouse Muscle in Vivo \| Science.” Accessed: Jan. 23, 2024. [Online]. Available: https://www.science.org/doi/10.1126/science.1690918 [93]K. Karikó, M. Buckstein, H. Ni, and D. Weissman, “Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA,” Immunity, vol. 2, no. 23, pp. 165–175, 2005, doi: 10.1016/j.immuni.2005.06.008. [94]SEC, “CellScipt & BioNTech. Patent sublicense agreement. EX-10.15. SEC.” Accessed: Jan. 23, 2024. [Online]. Available: https://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1015.htm [95]SEC, “CellScipt & Moderna. Patent sublicense agreement. EX-10.8. SEC,.” Accessed: Jan. 23, 2024. [Online]. Available: https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex108.htm [96]K. Karikó et al., “Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability,” Mol Ther, vol. 16, no. 11, pp. 1833–1840, Nov. 2008, doi: 10.1038/mt.2008.200. [97]蘇保衛 and 劉春傑：〈核酸疫苗全球專利簡析〉，《中國農業大學學報》，27(8)，2022，140–148頁。 [98]L. Warren et al., “Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA,” Cell Stem Cell, vol. 7, no. 5, pp. 618–630, Nov. 2010, doi: 10.1016/j.stem.2010.08.012. [99]Bryn B, “Science: The Breakthroughs of 2010 and Insights of the Decade \| American Association for the Advancement of Science (AAAS).” Accessed: Jan. 23, 2024. [Online]. Available: https://www.aaas.org/news/science-breakthroughs-2010-and-insights-decade [100] TIME, “Derrick Rossi - Person of the Year 2010 - TIME.” Accessed: Jan. 23, 2024. [Online]. Available: https://content.time.com/time/specials/packages/article/0,28804,2036683_2036767_2037437,00.html [101] A. J. Geall et al., “Nonviral delivery of self-amplifying RNA vaccines,” Proc Natl Acad Sci U S A, vol. 109, no. 36, pp. 14604–14609, Sep. 2012, doi: 10.1073/pnas.1209367109. [102] M. Alberer et al., “Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial,” The Lancet, vol. 390, no. 10101, pp. 1511–1520, Sep. 2017, doi: 10.1016/S0140-6736(17)31665-3. [103] K. Bahl et al., “Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses,” Mol Ther, vol. 25, no. 6, pp. 1316–1327, Jun. 2017, doi: 10.1016/j.ymthe.2017.03.035. [104] P. L. Felgner et al., “Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.,” Proceedings of the National Academy of Sciences, vol. 84, no. 21, pp. 7413–7417, Nov. 1987, doi: 10.1073/pnas.84.21.7413. [105] S. Slaughter and L. L. Leslie, Academic Capitalism: Politics, Policies, and the Entrepreneurial University. The Johns Hopkins University Press, 2715 North Charles Street, Baltimore, MD 21218-4319 ($39, 1997. [106] J. Hakala and O.-H. Ylijoki, “Research for Whom? Research Orientations in Three Academic Cultures,” Organization, vol. 8, no. 2, pp. 373–380, May 2001, doi: 10.1177/1350508401082021. [107] P. J. Bentley, M. Gulbrandsen, and S. Kyvik, “The relationship between basic and applied research in universities,” High Educ, vol. 70, no. 4, pp. 689–709, Oct. 2015, doi: 10.1007/s10734-015-9861-2. [108] H.-L. Zhang, “Current status and patent prospective of lipid nanoparticle for mRNA delivery,” Expert Opinion on Therapeutic Patents, vol. 33, no. 2, pp. 125–131, Feb. 2023, doi: 10.1080/13543776.2023.2195541. [109] R. Tenchov, R. Bird, A. E. Curtze, and Q. Zhou, “Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement,” ACS Nano, vol. 15, no. 11, pp. 16982–17015, Nov. 2021, doi: 10.1021/acsnano.1c04996. [110] A. Muheem et al., “Recent Patents, Regulatory Issues, and Toxicity of Nanoparticles in Neuronal Disorders,” Current Drug Metabolism, vol. 22, no. 4, pp. 263–279, Apr. 2021, doi: 10.2174/1389200221999201210213036. [111] R. Paliwal, S. R. Paliwal, R. Kenwat, B. D. Kurmi, and M. K. Sahu, “Solid lipid nanoparticles: a review on recent perspectives and patents,” Expert Opinion on Therapeutic Patents, vol. 30, no. 3, pp. 179–194, Mar. 2020, doi: 10.1080/13543776.2020.1720649. [112] C. Martin and D. Lowery, “mRNA vaccines: intellectual property landscape.,” Nature Reviews Drug Discovery, vol. 19, no. 9, pp. 578–579, Sep. 2020. [113] L. Battaglia and E. Ugazio, “Lipid Nano- and Microparticles: An Overview of Patent-Related Research,” Journal of Nanomaterials, vol. 2019, p. e2834941, Jan. 2019, doi: 10.1155/2019/2834941. [114] U. Storz, “The patent maze of COVID 19 vaccines,” Expert Opinion on Therapeutic Patents, vol. 31, no. 12, pp. 1177–1188, Dec. 2021, doi: 10.1080/13543776.2021.1945581. [115] Web of Science Group, “Web of Science platform,” Clarivate. Accessed: Jan. 23, 2024. [Online]. Available: https://clarivate.com/products/scientific-and-academic-research/research-discovery-and-workflow-solutions/webofscience-platform/ [116] WIPO, “WIPO - Search International and National Patent Collections.” Accessed: Jan. 23, 2024. [Online]. Available: https://patentscope.wipo.int/search/en/search.jsf [117] Wikipedia, “Drew Weissman,” Wikipedia. Dec. 11, 2023. Accessed: Jan. 23, 2024. [Online]. Available: https://en.wikipedia.org/w/index.php?title=Drew_Weissman&oldid=1189424898 [118] “Norbert Pardi, Ph.D.,” RNA Innovation. Accessed: Jan. 23, 2024. [Online]. Available: https://rnainnovation.med.upenn.edu/people/norbert-pardi-ph-d-2/ [119] “Ying Tam, M.Sc., Ph.D,” Acuitas. Accessed: Jan. 23, 2024. [Online]. Available: https://acuitastx.com/company/ying-tam-msc-ph-d/ [120] “Mohamad-Gabriel Alameh, Ph.D.,” RNA Innovation. Accessed: Jan. 23, 2024. [Online]. Available: https://rnainnovation.med.upenn.edu/people/mohamad-gabriel-alameh-ph-d/ [121] camiel, “Big Pharma raked in USD 90 billion in profits with COVID-19 vaccines,” SOMO. Accessed: Jun. 22, 2023. [Online]. Available: https://www.somo.nl/big-pharma-raked-in-usd-90-billion-in-profits-with-covid-19-vaccines/ [122] Kevin Dunleavy, “Pfizer sees COVID-19 product sales plummeting in 2023.” Accessed: Jun. 22, 2023. [Online]. Available: https://www.fiercepharma.com/pharma/pfizer-sees-covid-19-vaccine-sales-falling-64-2023-paxlovid-declining-58 [123] BioNTech, “BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update \| BioNTech,” BioNTech. Accessed: Jul. 31, 2023. [Online]. Available: https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial/ [124] Moderna, “Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates.” Accessed: Jul. 31, 2023. [Online]. Available: https://investors.modernatx.com/news/news-details/2022/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2021-Financial-Results-and-Provides-Business-Updates/default.aspx [125] Moderna, “Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates.” Accessed: Jul. 31, 2023. [Online]. Available: https://investors.modernatx.com/news/news-details/2023/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2022-Financial-Results-and-Provides-Business-Updates/default.aspx [126] E. Dolgin, “The tangled history of mRNA vaccines.,” Nature, pp. 318–324, 2021. [127] SEC, “Arbutus Injunction Survives Attempted Appeal by Acuitas.” Accessed: Jan. 23, 2024. [Online]. Available: https://www.sec.gov/Archives/edgar/data/1447028/000117184317002101/exh_991.htm [128] Arbutus, “Arbutus Settles Litigation, Terminating Acuitas’ Rights to LNP Technology \| Arbutus Biopharma Corporation.” Accessed: Jan. 23, 2024. [Online]. Available: https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-settles-litigation-terminating-acuitas-rights-lnp-0 [129] Y. Christopher and bloomberglaw, “Arbutus Is Sued Over Pfizer’s Covid Vaccine Delivery Tech (1).” Accessed: Jan. 23, 2024. [Online]. Available: https://news.bloomberglaw.com/ip-law/arbutus-sued-by-supplier-of-pfizers-covid-vaccine-delivery-tech [130] S. Daniel and S. Andrew, “The mRNA IP and Competitive Landscape: Translate BIO; Arcturus; eTheRNA and Other Startups; and LNP Technology (Part II),” JD Supra. Accessed: Jan. 23, 2024. [Online]. Available: https://www.jdsupra.com/legalnews/the-mrna-ip-and-competitive-landscape-8652492/ [131] BioNTech, “BioNTech and Genevant Sciences Sign Strategic mRNA-Focused Partnership in Rare Diseases \| BioNTech.” Accessed: Jan. 23, 2024. [Online]. Available: https://investors.biontech.de/news-releases/news-release-details/biontech-and-genevant-sciences-sign-strategic-mrna-focused/ [132] 1:22-cv-02229 - Acuitas Therapeutics Inc v. Genevant Sciences GMBH et al. \| Unified Patents. 2023. Accessed: Jan. 23, 2024. [Online]. Available: https://portal.unifiedpatents.com/litigation/New%20York%20Southern%20District%20Court/case/1:22-cv-02229 [133] Arbutus Biopharma, “Advancing our mission through collaboration.,” Arbutus Biopharma. Accessed: Jan. 23, 2024. [Online]. Available: https://www.arbutusbio.com/partnering/ [134] CureVac, “About Us,” CureVac. Accessed: Jan. 23, 2024. [Online]. Available: https://www.curevac.com/en/about-us/ [135] Alnylam, “RNAi Therapeutics \| How RNA Interference Works \| Alnylam® Pharmaceuticals,” RNAi Therapeutics \| How RNA Interference Works \| Alnylam® Pharmaceuticals. Accessed: Jan. 23, 2024. [Online]. Available: https://www.alnylam.com/our-science/the-science-of-rnai [136] “INEX Pharmaceuticals Announces Completion of Spin-out of Tekmira Pharmaceuticals Corporation and Closed a $5.3 Million Convertible Debenture Financing,” BioSpace. Accessed: Jan. 23, 2024. [Online]. Available: https://www.biospace.com/article/inex-pharmaceuticals-announces-completion-of-spin-out-of-tekmira-pharmaceuticals-corporation-and-closed-a-5-3-million-convertible-debenture-financing/ [137] Bio space, “Tekmira Pharmaceuticals Corporation Sues Alnylam Pharmaceuticals for $1 Billion, Accusing Partner of Misusing RNAi Trade Secrets,” BioSpace. Accessed: Jan. 23, 2024. [Online]. Available: https://www.biospace.com/article/tekmira-pharmaceuticals-corporation-sues-alnylam-pharmaceuticals-for-1-billion-accusing-partner-of-misusing-rnai-trade-secrets-/ [138] Doug Macron, “Alnylam, Tekmira End Litigation with $65M Settlement,” GenomeWeb. Accessed: Jan. 23, 2024. [Online]. Available: https://www.genomeweb.com/gene-silencinggene-editing/alnylam-tekmira-end-litigation-65m-settlement [139] D. Garde, “Tekmira changes its name and shuffles away from Ebola \| Fierce Biotech.” Accessed: Jan. 23, 2024. [Online]. Available: https://www.fiercebiotech.com/r-d/tekmira-changes-its-name-and-shuffles-away-from-ebola [140] Arbutus, “Arbutus Licenses LNP Delivery Technology to Alexion for Use in Single Messenger RNA Product Candidate \| Arbutus Biopharma Corporation.” Accessed: Jan. 23, 2024. [Online]. Available: https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-licenses-lnp-delivery-technology-alexion-use-single [141] Biospace, “Alexion Redefines R&D Strategy, Discontinues Programs and Kills Deals With Moderna, Blueprint and Arbutus Biopharma,” BioSpace. Accessed: Jan. 23, 2024. [Online]. Available: https://www.biospace.com/article/alexion-redefines-r-and-d-strategy-discontinues-programs-and-kills-deals-with-moderna-blueprint-and-arbutus-biopharma-/ [142] Arbutus, “Arbutus,” Arbutus Biopharma. Accessed: Jan. 23, 2024. [Online]. Available: https://www.arbutusbio.com/ [143] Arbutus Biopharma, “A pipeline of powerful possibilities.,” Arbutus Biopharma. Accessed: Jan. 23, 2024. [Online]. Available: https://www.arbutusbio.com/pipeline/ [144] BioNTech, “BioNTech \| Grundlagenforschung und neuartige Immuntherapien.” Accessed: Jan. 23, 2024. [Online]. Available: https://www.biontech.com/de/de/home/about/who-we-are/vision-and-mission.html [145] SEC, “BioNTech and Genevant. License and co-development agreement. EX-10.17.” Accessed: Jan. 23, 2024. [Online]. Available: https://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1017.htm [146] SEC, “Pfizer & BioNTech. Research collaboration and license agreement. EX-10.18.” Accessed: Jan. 23, 2024. [Online]. Available: https://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1018.htm [147] SEC, “BioNTech. Registration form F-1.” Accessed: Jan. 23, 2024. [Online]. Available: https://www.sec.gov/Archives/edgar/data/1776985/000119312520195911/d939702df1.htm [148] 鍵凱科技：〈mRNA公司的主流核心專利技術〉，2024年1月24日，取自 https://www.jenkem.com/news/64.html [149] “About Us - Acuitas Therapeutics Company in Vancouver, BC,” Acuitas. Accessed: Jan. 23, 2024. [Online]. Available: https://acuitastx.com/company/our-journey/ [150] Moderna, “Pioneering mRNA technology,” Moderna. Accessed: Jan. 23, 2024. [Online]. Available: https://www.modernatx.com/zh-TW/ [151] SEC, “Arbutus Biopharma Corporation. Form 8-K.” Accessed: Jan. 23, 2024. [Online]. Available: https://www.sec.gov/Archives/edgar/data/1447028/000117184318002661/f8k_041218.htm [152] Genevant Sciences, “About us,” Genevant Sciences Corporation. Accessed: Jan. 23, 2024. [Online]. Available: https://www.genevant.com/about-us/ [153] A. B. Corporation, “Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases,” GlobeNewswire News Room. Accessed: Jan. 23, 2024. [Online]. Available: https://www.globenewswire.com/news-release/2018/04/11/1468874/14025/en/Arbutus-and-Roivant-Launch-Genevant-Sciences-with-Industry-Leading-Platform-to-Develop-Broad-Range-of-RNA-Therapeutics-for-Genetic-Diseases.html [154] Pfizer, “Pfizer: One of the world’s premier biopharmaceutical companies.” Accessed: Jan. 23, 2024. [Online]. Available: https://www.pfizer.com/ [155] Sachi Fujimori, “Inside the Delivery Vehicles Critical to the Success of mRNA - mRNA Part 3 \| Pfizer.” Accessed: Jan. 23, 2024. [Online]. Available: https://www.pfizer.com/news/behind-the-science/inside-delivery-vehicles-critical-success [156] “Which patents cover the COVID-19 vaccine candidates for Moderna, AstraZeneca, J&J and Novovax?,” Markman Advisors. Accessed: Jun. 28, 2023. [Online]. Available: https://www.markmanadvisors.com/blog/2020/7/21/which-patents-cover-the-covid-19-vaccine-candidates-for-moderna-astrazeneca-jampj-and-novovax [157] Moderna, “Moderna’s Patents and pending patent applications,” Moderna. Accessed: Sep. 09, 2023. [Online]. Available: https://www.modernatx.com/en-US/patents [158] Mario Gaviria and Burcu Kilic, “BioNTech and Pfizer’s BNT162 Vaccine Patent Landscape,” Public Citizen. Accessed: Sep. 09, 2023. [Online]. Available: https://www.citizen.org/article/biontech-and-pfizers-bnt162-vaccine-patent-landscape/ [159] Intellectual Property Officer, Ministry of Economic Affairs, “Patent information related to marketed COVID-19 vaccines.” Accessed: Jun. 28, 2023. [Online]. Available: https://www.tipo.gov.tw/tw/cp-853-888241-0d50d-1.html [160] WIPO, “COVID-19 vaccine tracker and landscape,” WIPO. Accessed: Mar. 25, 2023. [Online]. Available: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines [161] Zachary Silbersher, “Which patents cover the COVID-19 vaccine candidates for Moderna, AstraZeneca, J&J and Novovax? — Markman Advisors,” Markman Advisors. Accessed: Jan. 23, 2024. [Online]. Available: https://www.markmanadvisors.com/blog/2020/7/21/which-patents-cover-the-covid-19-vaccine-candidates-for-moderna-astrazeneca-jampj-and-novovax [162] WTO, “TRIPS Waiver Proposal: A Compilation of Statements & reports.” Accessed: Jan. 23, 2024. [Online]. Available: https://www.twn.my/title2/intellectual_property/trips_waiver_proposal.htm [163] A. S. Rutschman, “Ministerial Decision on the Trips Agreement (WTO),” International Legal Materials, vol. 62, no. 2, pp. 289–294, Apr. 2023, doi: 10.1017/ilm.2022.47. [164] G. Van Overwalle, “Will Covid Patents Save the World?,” GRUR International, vol. 69, no. 9, pp. 883–884, Sep. 2020, doi: 10.1093/grurint/ikaa110. [165] Michael K. Jones, Sean P. McConnell, Lauren G. Alvarez, and Emily (Harmon) Newcomer, “What Is a ‘Patent Waiver’ Anyway? Zooming Out on the TRIPS COVID-19 IP Waiver Debate,” Troutman Pepper - What Is a “Patent Waiver” Anyway? Zooming Out on the TRIPS COVID-19 IP Waiver Debate. Accessed: Jan. 23, 2024. [Online]. Available: https://www.troutman.com/insights/what-is-a-patent-waiver-anyway-zooming-out-on-the-trips-covid-ip-waiver-debate.html [166] Z. Donald, “More on Leaked WTO COVID-19 Vaccine Patent Waiver Compromise,” Patent Docs. Accessed: Mar. 13, 2023. [Online]. Available: https://www.patentdocs.org/2022/03/more-on-leaked-wto-covid-19-vaccine-patent-waiver-compromise.html [167] K. B. Kumar, “Vaccine Patents Debate Risks Becoming a Sideshow,” May 2021. Accessed: Jan. 24, 2024. [Online]. Available: https://www.rand.org/pubs/commentary/2021/05/vaccine-patents-debate-risks-becoming-a-sideshow-in.html [168] Elaine Ruth Fletcher, “Pyrrhic Victory If WTO Agrees To Patent Waiver For COVID-19 Vaccines - Health Policy Watch.” Accessed: Jan. 24, 2024. [Online]. Available: https://healthpolicy-watch.news/pyrrhic-victory-if-wto-agrees-to-patent-waiver-for-covid-19-vaccines/ [169] P. Erfani, A. Binagwaho, M. J. Jalloh, M. Yunus, P. Farmer, and V. Kerry, “Intellectual property waiver for covid-19 vaccines will advance global health equity,” BMJ, vol. 374, p. n1837, Aug. 2021, doi: 10.1136/bmj.n1837. [170] Osborne Clarke, “Trade secrets remain the sticking point in global debate over a vaccine IP waiver.” Accessed: Jan. 24, 2024. [Online]. Available: https://www.osborneclarke.com/insights/trade-secrets-remain-sticking-point-global-debate-over-vaccine-ip-waiver [171] K. Breuninger, “Pfizer CEO opposes U.S. call to waive Covid vaccine patents, cites manufacturing and safety issues,” CNBC. Accessed: Jan. 24, 2024. [Online]. Available: https://www.cnbc.com/2021/05/07/pfizer-ceo-biden-backed-covid-vaccine-patent-waiver-will-cause-problems.html [172] P. Krishtel and R. Malpani, “Suspend intellectual property rights for covid-19 vaccines,” BMJ, vol. 373, p. n1344, May 2021, doi: 10.1136/bmj.n1344. [173] S. Chaudhuri, “Patent Protection and Access to COVID-19 Medical Products in Developing Countries.” Rochester, NY, Jun. 30, 2021. doi: 10.2139/ssrn.3902314. [174] B. N. Sampat and K. C. Shadlen, “The COVID-19 Innovation System,” Health Affairs, vol. 40, no. 3, pp. 400–409, Mar. 2021, doi: 10.1377/hlthaff.2020.02097. [175] “Open COVID Pledge,” Open Covid Pledge. Accessed: Jan. 24, 2024. [Online]. Available: https://opencovidpledge.org/ [176] Admin, “American University Assumes Stewardship of the Open COVID Pledge,” Open Covid Pledge. Accessed: Jan. 24, 2024. [Online]. Available: https://opencovidpledge.org/2021/05/03/american-university-assumes-stewardship-of-the-open-covid-pledge/ [177] Stanford University Office of Technology Licensing, “COVID-19 Technology Access Framework \| Office of Technology Licensing.” Accessed: Jan. 24, 2024. [Online]. Available: https://otl.stanford.edu/industry/technology-collections/covid-19/covid-19-technology-access-framework [178] AUTM, “COVID-19 Licensing Guidelines.” Accessed: Jan. 24, 2024. [Online]. Available: https://autm.net/about-tech-transfer/covid19/covid-19-licensing-guidelines [179] A. J. Stevens, “Commentary: University Technology Transfer Has Made a Significant Contribution to Fighting COVID-19 while Ensuring Global Access,” Healthc Policy, vol. 17, no. 4, pp. 26–36, May 2022, doi: 10.12927/hcpol.2022.26829. [180] WHO, “Covid-19 Technology Access Pool (C-TAP).” Accessed: Jan. 24, 2024. [Online]. Available: https://covid19response.org/c-tap/ [181] E. Sukkar, “Patent pools: an idea whose time has come,” BMJ, vol. 338, p. b1630, Apr. 2009, doi: 10.1136/bmj.b1630. [182] EMILY BAUMGAERTNER, “Pfizer-BioNTech, Moderna refused to join WHO’s C-TAP for vaccines. Now the India surge is causing crisis. - Los Angeles Times.” Accessed: Jan. 24, 2024. [Online]. Available: https://www.latimes.com/world-nation/story/2021-04-30/vaccine-companies-and-the-u-s-government-snubbed-who-initiative-to-scale-up-global-manufacturing [183] Sara Jerving, “Moderna’s patents stand in way of mRNA vaccine hub’s grand vision \| Devex.” Accessed: Jan. 24, 2024. [Online]. Available: https://www.devex.com/news/moderna-s-patents-stand-in-way-of-mrna-vaccine-hub-s-grand-vision-103055 [184] S. Jerving, “US forges partnership with South Africa’s mRNA tech transfer hub,” Devex. Accessed: Jan. 24, 2024. [Online]. Available: https://www.devex.com/news/sponsored/us-forges-partnership-with-south-africa-s-mrna-tech-transfer-hub-103598 [185] Afrigen, “Afrigen and NIH to Collaborate on mRNA Vaccine Production Research – Afrigen Biologics Vaccines.” Accessed: Jan. 24, 2024. [Online]. Available: https://www.afrigen.co.za/2022/07/08/afrigen-and-nih-to-collaborate-on-mrna-vaccine-production-research/ [186] “Moderna Announces Its Global Public Health Strategy.” Accessed: Jan. 24, 2024. [Online]. Available: https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Its-Global-Public-Health-Strategy/default.aspx [187] Hannah Kuchler, “Patent wars: Moderna’s battle for the spoils of Covid vaccines.” Accessed: Jan. 24, 2024. [Online]. Available: https://www.ft.com/content/5769f077-641e-4d37-adc6-7634c59b6d5d [188] KRISTA MAHR, “Moderna says it will ‘never’ enforce Covid-19 vaccine patents in dozens of low- and middle-income countries - POLITICO.” Accessed: Jan. 24, 2024. [Online]. Available: https://www.politico.com/news/2022/03/07/moderna-never-enforce-covid-vaccine-patents-low-income-countries-00014874 [189] J. Keenan, “Moderna to pour $500M into Africa to meet future mRNA vaccine manufacturing demand \| Fierce Pharma.” Accessed: Jan. 24, 2024. [Online]. Available: https://www.fiercepharma.com/manufacturing/moderna-to-build-500m-plant-africa-as-it-looks-to-meeting-future-vaccine-demand [190] F. Kansteiner, “BioNTech to ship modular mRNA factories to Africa starting this year \| Fierce Pharma.” Accessed: Jan. 24, 2024. [Online]. Available: https://www.fiercepharma.com/manufacturing/biontech-plots-first-modular-mrna-factory-africa-by-middle-2022 [191] Mandy Parrett, “BioNTech launches African vaccine production in Rwanda,” European Pharmaceutical Review. Accessed: Jan. 24, 2024. [Online]. Available: https://www.europeanpharmaceuticalreview.com/news/172615/biontech-launches-african-vaccine-production-in-rwanda/ [192] Pfizer, “Pfizer and BioNTech Announce Collaboration With Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa \| Pfizer.” Accessed: Jan. 24, 2024. [Online]. Available: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-collaboration-biovac [193] H.-C. Sung, “An Analytic Study On Permanent Injunction In Patent Litigations,” no. 4:2, pp. 2–7, Dec. 2015. [194] Konstanze Richter, “‘CureVac and Moderna might be filing patent suits – but their brakes are firmly on’ - JUVE Patent.” Accessed: Jan. 24, 2024. [Online]. Available: https://www.juve-patent.com/legal-commentary/curevac-and-moderna-might-be-filing-patent-suits-but-their-brakes-are-firmly-on/
指導教授	林澂宋皇志(Chen Lin Huang-Chih Sung)	審核日期	2024-1-29
推文	facebook plurk twitter funp google live udn HD myshare reddit netvibes friend youpush delicious baidu
網路書籤	Google bookmarks del.icio.us hemidemi myshare

博碩士論文 105888005 詳細資訊